BioXell neurology, genitourinary, musculoskeletal news
BioXell will restructure and reduce headcount by at least 14 (36%) to 25, with cuts coming from undisclosed areas to focus on BXL1H5 (formerly MNAC13). The humanized antibody against TrkA ( NTRK1, Neurotrophic tyrosine kinase receptor 1) is in preclinical development for chronic pain, with clinical trials planned for 1H11. BioXell licensed the compound from Lay Line Genomics S.p.A. (Rome, Italy) in 2006. The company may seek to sell or partner its elocalcitol and BXL746 programs. BioXell stopped development of elocalcitol for overactive bladder (OAB) and benign prostatic hyperplasia in April after a Phase IIb trial of the non-hypercalcemic vitamin D receptor (VDR) agonist missed its primary endpoint. BXL746, a vitamin D3 analog for prevention of post-surgical adhesions, has completed preclinical development. BioXell also will terminate its vitamin D3 and Triggering Receptors Expressed on Myeloid Cells (TREM) research programs (see BioCentury, Feb. 20, 2006, & April 13, 2009). ...